Your email has been successfully added to our mailing list.

×
0.00614152202937248 0.00614152202937248 -0.000890075656430872 -0.000890075656430872 -0.00133511348464625 -0.000890075656430872 -0.000890075656430872 -0.00178015131286162
Stock impact report

Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders

AbbVie, Inc (ABBV)  More Company Research Source: Business Wire
Last abbvie, inc earnings: 5/1 07:43 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF Leverages Caraway’s unique drug discovery platform and expertise in cellular clearanceCollaboration to focus on development of TMEM175 modulators in Parkinson’s disease and other neurodegenerative disorders CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced an exclusive, collaboration and option agreement with AbbVie (NYSE: ABBV) to develop and commercialize Caraway’s small molecule therapeutics targeting TMEM175, a potassium ion channel critical to lysosomal function implicated in both Parkinson’s disease (PD) and other neurodegenerative disorders.TMEM175 is a compelling target with strong genetic support. Loss of function mutations in TMEM175 are associated with reduced lysosomal efficiency in a subpopulation of PD patients, that can manifest as earlier age of disease onset or elevated risk of dementia relative to idiopathic PD. Under this collaboration, Caraway will continue to advance proprietary small molecule TMEM175 modulators, leveraging Caraway’s uniqu [Read more]
Impact snapshot Event time: ABBV
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ABBV alerts

from News Quantified
Opt-in for
ABBV alerts

from News Quantified